Lipocine Inc., a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, announced that an independent contractor posted on Lipocine’s website, without authorization from Lipocine, statements suggesting that TLANDO was approved by the U.S. Food and Drug Administration.
SALT LAKE CITY, Dec. 8, 2020 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that an independent contractor posted on Lipocine’s website (www.lipocine.com), without authorization from Lipocine, statements suggesting that TLANDO was approved by the U.S. Food and Drug Administration (“FDA”). TLANDO has not received final approval from the FDA. Upon learning of the unauthorized posting to its website, Lipocine deleted the incorrect posting.
View original content to download multimedia:http://www.prnewswire.com/news-releases/lipocine-announces-deletion-of-unauthorized-changes-to-companys-website-301188971.html
SOURCE Lipocine Inc.
Company Codes: NASDAQ-SMALL:LPCN
